Payment overview · 2025
General Payments
$430.81
8 reported records · 4 companies
Healthcare provider profile · identity verified
Victor A Hernandez, MD
Allopathic & Osteopathic Physicians|General Practice · SAN JUAN, PR · NPI 1144496555
Verified facts
What the public records show
CMS Open Payments records show Victor A Hernandez, MD received $430.81 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Lokelma.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.23 | 39.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.92 | 35.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $85.76 | 19.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.90 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $430.81 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $152.92 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $142.61 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $85.76 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 253 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 216 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
253 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
240 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1580 | 311 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1363 | 213 |
| Losartan Potassium | Losartan Potassium | 1257 | 256 |
| Gabapentin | Gabapentin | 1073 | 215 |
| Famotidine | Famotidine | 979 | 188 |
| Omeprazole | Omeprazole | 850 | 168 |
| Simvastatin | Simvastatin | 767 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 750 | 169 |
| Donepezil Hcl | Donepezil Hcl | 725 | 128 |
| Metformin Hcl | Metformin Hcl | 690 | 136 |
| Lisinopril | Lisinopril | 647 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 629 | 128 |
| Sertraline Hcl | Sertraline Hcl | 476 | 95 |
| Memantine Hcl | Memantine Hcl | 474 | 80 |
| Furosemide | Furosemide | 447 | 78 |
| Alendronate Sodium | Alendronate Sodium | 434 | 95 |
| Trazodone Hcl | Trazodone Hcl | 403 | 77 |
| Temazepam | Temazepam | 394 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 379 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 353 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 347 | 75 |
| Montelukast Sodium | Montelukast Sodium | 341 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 323 | 73 |
| Quetiapine Fumarate | Quetiapine Fumarate | 321 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 86 |
| Synthroid | Levothyroxine Sodium | 305 | 59 |
| Clonazepam | Clonazepam | 298 | 64 |
| Buspirone Hcl | Buspirone Hcl | 281 | 63 |
| Carvedilol | Carvedilol | 272 | 54 |
| Pentoxifylline | Pentoxifylline | 272 | 48 |
| Farxiga | Dapagliflozin Propanediol | 253 | 39 |
| Mirtazapine | Mirtazapine | 248 | 49 |
| Eliquis | Apixaban | 240 | 40 |
| Nifedipine Er | Nifedipine | 233 | 28 |
| Azithromycin | Azithromycin | 231 | 153 |
| Citalopram Hbr | Citalopram Hydrobromide | 230 | 38 |
| Jardiance | Empagliflozin | 216 | 37 |
| Levetiracetam | Levetiracetam | 216 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 213 | 42 |
| Risperidone | Risperidone | 199 | 45 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 194 | 105 |
| Dexamethasone | Dexamethasone | 184 | 124 |
| Megestrol Acetate | Megestrol Acetate | 180 | 40 |
| Cilostazol | Cilostazol | 179 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 175 | 131 |
| Hydralazine Hcl | Hydralazine Hcl | 163 | 29 |
| Irbesartan | Irbesartan | 163 | 33 |
| Glimepiride | Glimepiride | 148 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 147 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 145 | 30 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 144 | 21 |
| Finasteride | Finasteride | 139 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 37 |
| Diclofenac Potassium | Diclofenac Potassium | 126 | 51 |
| Folic Acid | Folic Acid | 123 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 118 | 25 |
| Ezetimibe | Ezetimibe | 117 | 38 |
| Spironolactone | Spironolactone | 113 | 15 |
| Latanoprost | Latanoprost | 110 | 18 |
| Permethrin | Permethrin | 106 | 81 |
| Baclofen | Baclofen | 96 | 12 |
| Meclizine Hcl | Meclizine Hcl | 94 | 38 |
| Meloxicam | Meloxicam | 94 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 94 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 35 |
| Candesartan Cilexetil | Candesartan Cilexetil | 90 | 18 |
| Tradjenta | Linagliptin | 89 | 17 |
| Atenolol | Atenolol | 87 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 31 |
| Levofloxacin | Levofloxacin | 85 | 63 |
| Synjardy | Empagliflozin/Metformin Hcl | 84 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | 15 |
| Nabumetone | Nabumetone | 81 | 39 |
| Enalapril Maleate | Enalapril Maleate | 80 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 79 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | 11 |
| Betamethasone Valerate | Betamethasone Valerate | 74 | 38 |
| Insulin Lispro | Insulin Lispro | 74 | 14 |
| Methotrexate | Methotrexate Sodium | 74 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 74 | 14 |
| Mupirocin | Mupirocin | 73 | 52 |
| Potassium Chloride | Potassium Chloride | 72 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 22 |
| Lorazepam | Lorazepam | 70 | 22 |
| Glipizide | Glipizide | 69 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 65 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 64 | 40 |
| Ivermectin | Ivermectin | 63 | 54 |
| Memantine Hcl Er | Memantine Hcl | 63 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | suppressed |
| Glipizide Er | Glipizide | 61 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 15 |
| Galantamine Er | Galantamine Hbr | 59 | suppressed |
| Lactulose | Lactulose | 58 | 23 |
| Ramipril | Ramipril | 57 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 53 | 45 |
| Fenofibrate | Fenofibrate | 53 | 11 |
| Valsartan | Valsartan | 53 | 14 |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | suppressed |
| Fluconazole | Fluconazole | 51 | 36 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 51 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 11 |
| Gemfibrozil | Gemfibrozil | 50 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 50 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Humulin N | Insulin Nph Human Isophane | 48 | suppressed |
| Prednisone | Prednisone | 48 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 47 | 16 |
| Digoxin | Digoxin | 46 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 46 | 28 |
| Divalproex Sodium | Divalproex Sodium | 45 | 12 |
| Alprazolam | Alprazolam | 43 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 43 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 35 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Estazolam | Estazolam | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Humalog | Insulin Lispro | 36 | suppressed |
| Rivastigmine | Rivastigmine | 36 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 33 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 33 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 17 |
| Prodigy Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 31 | suppressed |
| Anastrozole | Anastrozole | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Lumigan | Bimatoprost | 28 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Primidone | Primidone | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Humulin R | Insulin Regular, Human | 23 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 14 |
| Naproxen | Naproxen | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 21 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 20 | 15 |
| Mometasone Furoate | Mometasone Furoate | 20 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | 14 |
| Ammonium Lactate | Ammonium Lactate | 19 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 11 |
| Methimazole | Methimazole | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 14 |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Lotrel | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $430.81 · 8 records | AstraZeneca Pharmaceuticals LP | COBENFY, Cologuard Collection Kit, FARXIGA, JARDIANCE, LOKELMA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error